MorphoSys AG
NASDAQ:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
NASDAQ:MOR
Watchlist
Price: 18.96 USD 2.43% Market Closed
Market Cap: $2.9B

Net Margin

-226.2%
Current
Declining
by 173%
vs 3-y average of -53.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-226.2%
=
Net Income
€-460.3m
/
Revenue
€203.5m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-226.2%
=
Net Income
$-460.3m
/
Revenue
€203.5m

Peer Comparison

Country Company Market Cap Net
Margin
DE
MorphoSys AG
XETRA:MOR
2.5B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 95% of companies in Germany
Percentile
5th
Based on 3 835 companies
5th percentile
-226.2%
Low
-222 027.4% — -2%
Typical Range
-2% — 6%
High
6% — 85 055.6%
Distribution Statistics
Germany
Min -222 027.4%
30th Percentile -2%
Median 2.2%
70th Percentile 6%
Max 85 055.6%

MorphoSys AG
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MOR Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-226.2%
=
Net Income
€-460.3m
/
Revenue
€203.5m
What is MorphoSys AG's current Net Margin?

The current Net Margin for MorphoSys AG is -226.2%, which is below its 3-year median of -53.2%.

How has Net Margin changed over time?

Over the last 3 years, MorphoSys AG’s Net Margin has decreased from -142.8% to -226.2%. During this period, it reached a low of -436.4% on Jun 30, 2022 and a high of 35.1% on Sep 30, 2023.

Back to Top